VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Select Topic:
Browse by Series:

Introduction: Therapeutic Advances in mCRPC

Panelists: Philippa J. Cheetham, MD, Stonybrook University;Raoul S. Concepcion, MD, Urology Associates, PC; Kenneth M. Kernen, MD, Michigan Urology;
Published: Wednesday, May 28, 2014

For High-Definition, Click
Moderator Raoul S. Concepcion, MD, introduces a panel discussion that highlights specific clinical information on therapeutic advances and remaining unmet challenges in the treatment of patients with castration-resistant prostate cancer (CRPC). The conversation includes expert perspectives from Philippa J. Cheetham, MD, Kenneth M. Kernen, MD, A. Oliver Sartor, MD, Neal D. Shore, MD, and Michael E. Williams, MD.

CRPC is defined by disease progression despite the administration of androgen deprivation therapy (ADT), notes Concepcion. Additionally, CRPC is characterized by a serum testosterone level less than 50 ng/dL and a rise in serum PSA. Patients without detectable metastases have M0 disease whereas those with metastases detected by radiographic imaging, either CT scan or NaF PET/CT, are said to have M1 CRPC, notes Concepcion.

In the last four years, five novel agents have demonstrated improved survival in metastatic CRPC and have been granted FDA approval, Concepcion points out. These newly approved agents include cabazitaxel, sipuleucel-T, abiraterone acetate, enzalutamide, and radium-223.

Slider Left
Slider Right
For High-Definition, Click
Moderator Raoul S. Concepcion, MD, introduces a panel discussion that highlights specific clinical information on therapeutic advances and remaining unmet challenges in the treatment of patients with castration-resistant prostate cancer (CRPC). The conversation includes expert perspectives from Philippa J. Cheetham, MD, Kenneth M. Kernen, MD, A. Oliver Sartor, MD, Neal D. Shore, MD, and Michael E. Williams, MD.

CRPC is defined by disease progression despite the administration of androgen deprivation therapy (ADT), notes Concepcion. Additionally, CRPC is characterized by a serum testosterone level less than 50 ng/dL and a rise in serum PSA. Patients without detectable metastases have M0 disease whereas those with metastases detected by radiographic imaging, either CT scan or NaF PET/CT, are said to have M1 CRPC, notes Concepcion.

In the last four years, five novel agents have demonstrated improved survival in metastatic CRPC and have been granted FDA approval, Concepcion points out. These newly approved agents include cabazitaxel, sipuleucel-T, abiraterone acetate, enzalutamide, and radium-223.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x